FCB-Pharmicell

FCB-Pharmicell, as a company specializing in the research and development of stem cell drugs, has developed the stem cell therapeutic drug Hearticellgram-AMI for acute myocardial infarction after years of research and testing. On July 1, 2011, it received formal approval from the Korea Food and Drug Safety Administration for market release, becoming the world's first approved stem cell drug.